{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:11:07Z","timestamp":1788865867000,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijantimicag.2026.107923","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:36:42Z","timestamp":1783751802000},"page":"107923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extended vs. standard bedaquiline treatment for MDR\/RR-TB: A 5-year multi-centre study on clinical outcomes and cardiac safety in China"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6247-3252","authenticated-orcid":false,"given":"Wei","family":"Jing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingdong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiguang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naihui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107923_bib0001","series-title":"Global TB report 2024","year":"2024"},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0002","doi-asserted-by":"crossref","first-page":"100405","DOI":"10.1016\/j.jctube.2023.100405","article-title":"Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: an updated systematic review and meta-analysis","volume":"34","author":"Ur Rehman","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0003","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0004","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12879-022-07693-9","article-title":"Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR\/MDR\/XDR-tuberculosis: a retrospective cohort study in East China","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0005","series-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment","year":"2022"},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0006","unstructured":"World Health Organization. A Practical Handbook on the Pharmacovigilance of Medicines used in the Treatment of Tuberculosis: Enhancing the Safety of the TB Patient. Geneva: World Health Organization; 2012. www.who.int\/docs\/default-source\/documents\/tuberculosis\/apractical-handbook-on-the-pharmacovigilance-of-medicines-used-in-the-treatment-oftuberculosis.pdf?sfvrsn=6e5fc0cf_5."},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0007","series-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis","year":"2014"},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0008","series-title":"Common terminology criteria for adverse events (CTCAE) v5.0","year":"2017"},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0009","article-title":"Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis","volume":"49","author":"Guglielmetti","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0010","article-title":"The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR\/RR-TB cohort","volume":"10","author":"Khan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0011","doi-asserted-by":"crossref","first-page":"00685","DOI":"10.1183\/23120541.00685-2021","article-title":"Safety of prolonged treatment with bedaquiline in programmatic conditions","volume":"8","author":"Zhurkin","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0012","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1473-3099(21)00811-2","article-title":"Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study","volume":"22","author":"Ndjeka","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0013","article-title":"Emergence of bedaquiline resistance in a high tuberculosis burden country","volume":"59","author":"Chesov","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0014","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12879-025-11067-2","article-title":"Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"25","author":"Hu","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107923_bib0015","series-title":"Key updates to the treatment of drug-resistant tuberculosis: rapid communication","year":"2024"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926002104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:48:55Z","timestamp":1788864535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926002104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0924857926002104"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107923","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended vs. standard bedaquiline treatment for MDR\/RR-TB: A 5-year multi-centre study on clinical outcomes and cardiac safety in China","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107923"}}